Global Cachexia Treatment Market
Global Cachexia Treatment Market

Cachexia Treatment Comprehensive Study by Application (Cancer, Chronic Kidney Disease, Congestive Heart Failure (CHF), Cystic Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis), Drug (Dronabinol, Mega Sterol Acetate, Corticosteroids, Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Drug Class (Weight Loss Stabilizers, Appetite Stimulants, Progestogens, Combination therapies, Others), End User (Hospitals, Homecare, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2026

Cachexia Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 203 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Cachexia Treatment Market Overview:
Cachexia is a disorder that causes extreme weight loss and muscle wasting and can include loss of body fat. This syndrome affects people who are in the late stages of serious diseases like cancer, HIV or AIDS, COPD, kidney disease, and congestive heart failure (CHF). There is no specific treatment or way to reverse cachexia. The goal of treatment is to improve symptoms and quality of life. Current therapy for cachexia includes appetite stimulants such as megestrol acetate (Megace), drugs, such as dronabinol (Marinol), to improve nausea, appetite, and mood, medications that decrease inflammation and diet changes, nutritional supplements and adapted exercise

Growth Drivers
  • Rise Cases of a Chronic Condition such as Cancer
  • Availability of Advanced Healthcare Facilities in Developing Countries

Market Trends
  • Huge Investment in R&D in Development of Drugs by Major Market Players

Roadblocks
  • Adverse Effect Associated with Cachexia Therapy

Opportunities
  • Increase in Awareness about the Cachexia Treatment
  • Development of Health Care Infrastructure in Developed as well as Developing Countries

Challenges
  • The Stringent Regulatory Requirements and the Long Procedure for FDA Approval


Competitive Landscape:
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Pfizer Inc (United States), Merck & Co. Inc. (United States), Aphios Corporation (United States), Benuvia Therapeutics Inc (United States), Alkem Labs (India), Lannett (United States), Ascent Pharmaceuticals, Inc (United States), Akorn Incorporated (United States), Endo International Inc (Ireland), Hikma Pharmaceuticals PLC (United Kingdom) and Teva Pharmaceutical Industries Ltd (Israel). Additionally, following companies can also be profiled that are part of our coverage like Wockhardt (India) and Breckenridge Pharmaceutical, Inc (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Cachexia Treatment market by 2026. Considering Market by Drug, the sub-segment i.e. Dronabinol will boost the Cachexia Treatment market. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Cachexia Treatment market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Cachexia Treatment market. Considering Market by Drug Class, the sub-segment i.e. Weight Loss Stabilizers will boost the Cachexia Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Cachexia Treatment market.

In Dec 2020, Actimed Therapeutics announces that it has been granted US patent US 10,828,270 expanding its intellectual property rights directed to ACM-002 (S-oxprenolol) for the treatment of cancer cachexia. and In Feb 2020, NGM Biopharmaceuticals, Inc. announced the initiation of a Phase 1a/1b clinical study of NGM120, a first-in-class antagonistic antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling, for the potential treatment of cancer and cancer anorexia/cachexia syndrome (CACS).

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cachexia Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cachexia Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Cachexia Treatment Treatment Providers, Healthcare Industry, Research Institutes, Government Agencies, Medical Research Laboratories and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Application
  • Cancer
  • Chronic Kidney Disease
  • Congestive Heart Failure (CHF)
  • Cystic Fibrosis
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rheumatoid Arthritis
By Drug
  • Dronabinol
  • Mega Sterol Acetate
  • Corticosteroids
  • Others

By Route of Administration
  • Oral
  • Parenteral

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Drug Class
  • Weight Loss Stabilizers
  • Appetite Stimulants
  • Progestogens
  • Combination therapies
  • Others

By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise Cases of a Chronic Condition such as Cancer
      • 3.2.2. Availability of Advanced Healthcare Facilities in Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. The Stringent Regulatory Requirements and the Long Procedure for FDA Approval
    • 3.4. Market Trends
      • 3.4.1. Huge Investment in R&D in Development of Drugs by Major Market Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cachexia Treatment, by Application, Drug, Route of Administration, Distribution Channel, Drug Class, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cachexia Treatment (Value)
      • 5.2.1. Global Cachexia Treatment by: Application (Value)
        • 5.2.1.1. Cancer
        • 5.2.1.2. Chronic Kidney Disease
        • 5.2.1.3. Congestive Heart Failure (CHF)
        • 5.2.1.4. Cystic Fibrosis
        • 5.2.1.5. Chronic Obstructive Pulmonary Disease (COPD)
        • 5.2.1.6. Rheumatoid Arthritis
      • 5.2.2. Global Cachexia Treatment by: Drug (Value)
        • 5.2.2.1. Dronabinol
        • 5.2.2.2. Mega Sterol Acetate
        • 5.2.2.3. Corticosteroids
        • 5.2.2.4. Others
      • 5.2.3. Global Cachexia Treatment by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
      • 5.2.4. Global Cachexia Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Online Pharmacy
        • 5.2.4.3. Retail Pharmacy
      • 5.2.5. Global Cachexia Treatment by: Drug Class (Value)
        • 5.2.5.1. Weight Loss Stabilizers
        • 5.2.5.2. Appetite Stimulants
        • 5.2.5.3. Progestogens
        • 5.2.5.4. Combination therapies
        • 5.2.5.5. Others
      • 5.2.6. Global Cachexia Treatment by: End User (Value)
        • 5.2.6.1. Hospitals
        • 5.2.6.2. Homecare
        • 5.2.6.3. Specialty Clinics
        • 5.2.6.4. Others
      • 5.2.7. Global Cachexia Treatment Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Cachexia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aphios Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Benuvia Therapeutics Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Alkem Labs (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lannett (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ascent Pharmaceuticals, Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Akorn Incorporated (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Endo International Inc (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Cachexia Treatment Sale, by Application, Drug, Route of Administration, Distribution Channel, Drug Class, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cachexia Treatment (Value)
      • 7.2.1. Global Cachexia Treatment by: Application (Value)
        • 7.2.1.1. Cancer
        • 7.2.1.2. Chronic Kidney Disease
        • 7.2.1.3. Congestive Heart Failure (CHF)
        • 7.2.1.4. Cystic Fibrosis
        • 7.2.1.5. Chronic Obstructive Pulmonary Disease (COPD)
        • 7.2.1.6. Rheumatoid Arthritis
      • 7.2.2. Global Cachexia Treatment by: Drug (Value)
        • 7.2.2.1. Dronabinol
        • 7.2.2.2. Mega Sterol Acetate
        • 7.2.2.3. Corticosteroids
        • 7.2.2.4. Others
      • 7.2.3. Global Cachexia Treatment by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
      • 7.2.4. Global Cachexia Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Online Pharmacy
        • 7.2.4.3. Retail Pharmacy
      • 7.2.5. Global Cachexia Treatment by: Drug Class (Value)
        • 7.2.5.1. Weight Loss Stabilizers
        • 7.2.5.2. Appetite Stimulants
        • 7.2.5.3. Progestogens
        • 7.2.5.4. Combination therapies
        • 7.2.5.5. Others
      • 7.2.6. Global Cachexia Treatment by: End User (Value)
        • 7.2.6.1. Hospitals
        • 7.2.6.2. Homecare
        • 7.2.6.3. Specialty Clinics
        • 7.2.6.4. Others
      • 7.2.7. Global Cachexia Treatment Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cachexia Treatment: by Application(USD Million)
  • Table 2. Cachexia Treatment Cancer , by Region USD Million (2015-2020)
  • Table 3. Cachexia Treatment Chronic Kidney Disease , by Region USD Million (2015-2020)
  • Table 4. Cachexia Treatment Congestive Heart Failure (CHF) , by Region USD Million (2015-2020)
  • Table 5. Cachexia Treatment Cystic Fibrosis , by Region USD Million (2015-2020)
  • Table 6. Cachexia Treatment Chronic Obstructive Pulmonary Disease (COPD) , by Region USD Million (2015-2020)
  • Table 7. Cachexia Treatment Rheumatoid Arthritis , by Region USD Million (2015-2020)
  • Table 8. Cachexia Treatment: by Drug(USD Million)
  • Table 9. Cachexia Treatment Dronabinol , by Region USD Million (2015-2020)
  • Table 10. Cachexia Treatment Mega Sterol Acetate , by Region USD Million (2015-2020)
  • Table 11. Cachexia Treatment Corticosteroids , by Region USD Million (2015-2020)
  • Table 12. Cachexia Treatment Others , by Region USD Million (2015-2020)
  • Table 13. Cachexia Treatment: by Route of Administration(USD Million)
  • Table 14. Cachexia Treatment Oral , by Region USD Million (2015-2020)
  • Table 15. Cachexia Treatment Parenteral , by Region USD Million (2015-2020)
  • Table 16. Cachexia Treatment: by Distribution Channel(USD Million)
  • Table 17. Cachexia Treatment Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 18. Cachexia Treatment Online Pharmacy , by Region USD Million (2015-2020)
  • Table 19. Cachexia Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 20. Cachexia Treatment: by Drug Class(USD Million)
  • Table 21. Cachexia Treatment Weight Loss Stabilizers , by Region USD Million (2015-2020)
  • Table 22. Cachexia Treatment Appetite Stimulants , by Region USD Million (2015-2020)
  • Table 23. Cachexia Treatment Progestogens , by Region USD Million (2015-2020)
  • Table 24. Cachexia Treatment Combination therapies , by Region USD Million (2015-2020)
  • Table 25. Cachexia Treatment Others , by Region USD Million (2015-2020)
  • Table 26. Cachexia Treatment: by End User(USD Million)
  • Table 27. Cachexia Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 28. Cachexia Treatment Homecare , by Region USD Million (2015-2020)
  • Table 29. Cachexia Treatment Specialty Clinics , by Region USD Million (2015-2020)
  • Table 30. Cachexia Treatment Others , by Region USD Million (2015-2020)
  • Table 31. South America Cachexia Treatment, by Country USD Million (2015-2020)
  • Table 32. South America Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 33. South America Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 34. South America Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 35. South America Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 36. South America Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 37. South America Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 38. Brazil Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 39. Brazil Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 40. Brazil Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 41. Brazil Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 42. Brazil Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 43. Brazil Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 44. Argentina Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 45. Argentina Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 46. Argentina Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 47. Argentina Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 48. Argentina Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 49. Argentina Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 50. Rest of South America Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 51. Rest of South America Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 52. Rest of South America Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 53. Rest of South America Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 54. Rest of South America Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 55. Rest of South America Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 56. Asia Pacific Cachexia Treatment, by Country USD Million (2015-2020)
  • Table 57. Asia Pacific Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 58. Asia Pacific Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 59. Asia Pacific Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 60. Asia Pacific Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 61. Asia Pacific Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 62. Asia Pacific Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 63. China Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 64. China Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 65. China Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 66. China Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 67. China Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 68. China Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 69. Japan Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 70. Japan Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 71. Japan Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 72. Japan Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 73. Japan Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 74. Japan Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 75. India Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 76. India Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 77. India Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 78. India Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 79. India Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 80. India Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 81. South Korea Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 82. South Korea Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 83. South Korea Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 84. South Korea Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 85. South Korea Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 86. South Korea Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 87. Taiwan Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 88. Taiwan Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 89. Taiwan Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 90. Taiwan Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 91. Taiwan Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 92. Taiwan Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 93. Australia Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 94. Australia Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 95. Australia Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 96. Australia Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 97. Australia Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 98. Australia Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 99. Rest of Asia-Pacific Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 100. Rest of Asia-Pacific Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 101. Rest of Asia-Pacific Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 102. Rest of Asia-Pacific Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 103. Rest of Asia-Pacific Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 104. Rest of Asia-Pacific Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 105. Europe Cachexia Treatment, by Country USD Million (2015-2020)
  • Table 106. Europe Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 107. Europe Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 108. Europe Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 109. Europe Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 110. Europe Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 111. Europe Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 112. Germany Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 113. Germany Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 114. Germany Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 115. Germany Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 116. Germany Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 117. Germany Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 118. France Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 119. France Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 120. France Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 121. France Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 122. France Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 123. France Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 124. Italy Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 125. Italy Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 126. Italy Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 127. Italy Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 128. Italy Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 129. Italy Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 130. United Kingdom Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 131. United Kingdom Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 132. United Kingdom Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 133. United Kingdom Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 134. United Kingdom Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 135. United Kingdom Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 136. Netherlands Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 137. Netherlands Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 138. Netherlands Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 139. Netherlands Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 140. Netherlands Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 141. Netherlands Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 142. Rest of Europe Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 143. Rest of Europe Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 144. Rest of Europe Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 145. Rest of Europe Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 146. Rest of Europe Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 147. Rest of Europe Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 148. MEA Cachexia Treatment, by Country USD Million (2015-2020)
  • Table 149. MEA Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 150. MEA Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 151. MEA Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 152. MEA Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 153. MEA Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 154. MEA Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 155. Middle East Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 156. Middle East Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 157. Middle East Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 158. Middle East Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 159. Middle East Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 160. Middle East Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 161. Africa Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 162. Africa Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 163. Africa Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 164. Africa Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 165. Africa Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 166. Africa Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 167. North America Cachexia Treatment, by Country USD Million (2015-2020)
  • Table 168. North America Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 169. North America Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 170. North America Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 171. North America Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 172. North America Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 173. North America Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 174. United States Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 175. United States Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 176. United States Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 177. United States Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 178. United States Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 179. United States Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 180. Canada Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 181. Canada Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 182. Canada Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 183. Canada Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 184. Canada Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 185. Canada Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 186. Mexico Cachexia Treatment, by Application USD Million (2015-2020)
  • Table 187. Mexico Cachexia Treatment, by Drug USD Million (2015-2020)
  • Table 188. Mexico Cachexia Treatment, by Route of Administration USD Million (2015-2020)
  • Table 189. Mexico Cachexia Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 190. Mexico Cachexia Treatment, by Drug Class USD Million (2015-2020)
  • Table 191. Mexico Cachexia Treatment, by End User USD Million (2015-2020)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Cachexia Treatment: by Application(USD Million)
  • Table 204. Cachexia Treatment Cancer , by Region USD Million (2021-2026)
  • Table 205. Cachexia Treatment Chronic Kidney Disease , by Region USD Million (2021-2026)
  • Table 206. Cachexia Treatment Congestive Heart Failure (CHF) , by Region USD Million (2021-2026)
  • Table 207. Cachexia Treatment Cystic Fibrosis , by Region USD Million (2021-2026)
  • Table 208. Cachexia Treatment Chronic Obstructive Pulmonary Disease (COPD) , by Region USD Million (2021-2026)
  • Table 209. Cachexia Treatment Rheumatoid Arthritis , by Region USD Million (2021-2026)
  • Table 210. Cachexia Treatment: by Drug(USD Million)
  • Table 211. Cachexia Treatment Dronabinol , by Region USD Million (2021-2026)
  • Table 212. Cachexia Treatment Mega Sterol Acetate , by Region USD Million (2021-2026)
  • Table 213. Cachexia Treatment Corticosteroids , by Region USD Million (2021-2026)
  • Table 214. Cachexia Treatment Others , by Region USD Million (2021-2026)
  • Table 215. Cachexia Treatment: by Route of Administration(USD Million)
  • Table 216. Cachexia Treatment Oral , by Region USD Million (2021-2026)
  • Table 217. Cachexia Treatment Parenteral , by Region USD Million (2021-2026)
  • Table 218. Cachexia Treatment: by Distribution Channel(USD Million)
  • Table 219. Cachexia Treatment Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 220. Cachexia Treatment Online Pharmacy , by Region USD Million (2021-2026)
  • Table 221. Cachexia Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 222. Cachexia Treatment: by Drug Class(USD Million)
  • Table 223. Cachexia Treatment Weight Loss Stabilizers , by Region USD Million (2021-2026)
  • Table 224. Cachexia Treatment Appetite Stimulants , by Region USD Million (2021-2026)
  • Table 225. Cachexia Treatment Progestogens , by Region USD Million (2021-2026)
  • Table 226. Cachexia Treatment Combination therapies , by Region USD Million (2021-2026)
  • Table 227. Cachexia Treatment Others , by Region USD Million (2021-2026)
  • Table 228. Cachexia Treatment: by End User(USD Million)
  • Table 229. Cachexia Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 230. Cachexia Treatment Homecare , by Region USD Million (2021-2026)
  • Table 231. Cachexia Treatment Specialty Clinics , by Region USD Million (2021-2026)
  • Table 232. Cachexia Treatment Others , by Region USD Million (2021-2026)
  • Table 233. South America Cachexia Treatment, by Country USD Million (2021-2026)
  • Table 234. South America Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 235. South America Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 236. South America Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 237. South America Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 238. South America Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 239. South America Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 240. Brazil Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 241. Brazil Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 242. Brazil Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 243. Brazil Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 244. Brazil Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 245. Brazil Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 246. Argentina Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 247. Argentina Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 248. Argentina Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 249. Argentina Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 250. Argentina Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 251. Argentina Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 252. Rest of South America Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 253. Rest of South America Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 254. Rest of South America Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 255. Rest of South America Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 256. Rest of South America Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 257. Rest of South America Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 258. Asia Pacific Cachexia Treatment, by Country USD Million (2021-2026)
  • Table 259. Asia Pacific Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 260. Asia Pacific Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 261. Asia Pacific Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 262. Asia Pacific Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 263. Asia Pacific Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 264. Asia Pacific Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 265. China Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 266. China Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 267. China Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 268. China Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 269. China Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 270. China Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 271. Japan Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 272. Japan Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 273. Japan Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 274. Japan Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 275. Japan Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 276. Japan Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 277. India Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 278. India Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 279. India Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 280. India Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 281. India Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 282. India Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 283. South Korea Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 284. South Korea Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 285. South Korea Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 286. South Korea Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 287. South Korea Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 288. South Korea Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 289. Taiwan Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 290. Taiwan Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 291. Taiwan Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 292. Taiwan Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 293. Taiwan Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 294. Taiwan Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 295. Australia Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 296. Australia Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 297. Australia Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 298. Australia Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 299. Australia Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 300. Australia Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 301. Rest of Asia-Pacific Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 302. Rest of Asia-Pacific Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 303. Rest of Asia-Pacific Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 304. Rest of Asia-Pacific Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 305. Rest of Asia-Pacific Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 306. Rest of Asia-Pacific Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 307. Europe Cachexia Treatment, by Country USD Million (2021-2026)
  • Table 308. Europe Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 309. Europe Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 310. Europe Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 311. Europe Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 312. Europe Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 313. Europe Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 314. Germany Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 315. Germany Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 316. Germany Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 317. Germany Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 318. Germany Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 319. Germany Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 320. France Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 321. France Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 322. France Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 323. France Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 324. France Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 325. France Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 326. Italy Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 327. Italy Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 328. Italy Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 329. Italy Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 330. Italy Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 331. Italy Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 332. United Kingdom Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 333. United Kingdom Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 334. United Kingdom Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 335. United Kingdom Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 336. United Kingdom Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 337. United Kingdom Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 338. Netherlands Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 339. Netherlands Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 340. Netherlands Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 341. Netherlands Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 342. Netherlands Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 343. Netherlands Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 344. Rest of Europe Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 345. Rest of Europe Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 346. Rest of Europe Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 347. Rest of Europe Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 348. Rest of Europe Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 349. Rest of Europe Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 350. MEA Cachexia Treatment, by Country USD Million (2021-2026)
  • Table 351. MEA Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 352. MEA Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 353. MEA Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 354. MEA Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 355. MEA Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 356. MEA Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 357. Middle East Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 358. Middle East Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 359. Middle East Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 360. Middle East Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 361. Middle East Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 362. Middle East Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 363. Africa Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 364. Africa Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 365. Africa Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 366. Africa Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 367. Africa Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 368. Africa Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 369. North America Cachexia Treatment, by Country USD Million (2021-2026)
  • Table 370. North America Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 371. North America Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 372. North America Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 373. North America Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 374. North America Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 375. North America Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 376. United States Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 377. United States Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 378. United States Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 379. United States Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 380. United States Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 381. United States Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 382. Canada Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 383. Canada Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 384. Canada Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 385. Canada Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 386. Canada Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 387. Canada Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 388. Mexico Cachexia Treatment, by Application USD Million (2021-2026)
  • Table 389. Mexico Cachexia Treatment, by Drug USD Million (2021-2026)
  • Table 390. Mexico Cachexia Treatment, by Route of Administration USD Million (2021-2026)
  • Table 391. Mexico Cachexia Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 392. Mexico Cachexia Treatment, by Drug Class USD Million (2021-2026)
  • Table 393. Mexico Cachexia Treatment, by End User USD Million (2021-2026)
  • Table 394. Research Programs/Design for This Report
  • Table 395. Key Data Information from Secondary Sources
  • Table 396. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cachexia Treatment: by Application USD Million (2015-2020)
  • Figure 5. Global Cachexia Treatment: by Drug USD Million (2015-2020)
  • Figure 6. Global Cachexia Treatment: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Cachexia Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Cachexia Treatment: by Drug Class USD Million (2015-2020)
  • Figure 9. Global Cachexia Treatment: by End User USD Million (2015-2020)
  • Figure 10. South America Cachexia Treatment Share (%), by Country
  • Figure 11. Asia Pacific Cachexia Treatment Share (%), by Country
  • Figure 12. Europe Cachexia Treatment Share (%), by Country
  • Figure 13. MEA Cachexia Treatment Share (%), by Country
  • Figure 14. North America Cachexia Treatment Share (%), by Country
  • Figure 15. Global Cachexia Treatment share by Players 2020 (%)
  • Figure 16. Global Cachexia Treatment share by Players (Top 3) 2020(%)
  • Figure 17. Global Cachexia Treatment share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 21. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co. Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Aphios Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 24. Aphios Corporation (United States) Revenue: by Geography 2020
  • Figure 25. Benuvia Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 26. Benuvia Therapeutics Inc (United States) Revenue: by Geography 2020
  • Figure 27. Alkem Labs (India) Revenue, Net Income and Gross profit
  • Figure 28. Alkem Labs (India) Revenue: by Geography 2020
  • Figure 29. Lannett (United States) Revenue, Net Income and Gross profit
  • Figure 30. Lannett (United States) Revenue: by Geography 2020
  • Figure 31. Ascent Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. Ascent Pharmaceuticals, Inc (United States) Revenue: by Geography 2020
  • Figure 33. Akorn Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 34. Akorn Incorporated (United States) Revenue: by Geography 2020
  • Figure 35. Endo International Inc (Ireland) Revenue, Net Income and Gross profit
  • Figure 36. Endo International Inc (Ireland) Revenue: by Geography 2020
  • Figure 37. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 39. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 40. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2020
  • Figure 41. Global Cachexia Treatment: by Application USD Million (2021-2026)
  • Figure 42. Global Cachexia Treatment: by Drug USD Million (2021-2026)
  • Figure 43. Global Cachexia Treatment: by Route of Administration USD Million (2021-2026)
  • Figure 44. Global Cachexia Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 45. Global Cachexia Treatment: by Drug Class USD Million (2021-2026)
  • Figure 46. Global Cachexia Treatment: by End User USD Million (2021-2026)
  • Figure 47. South America Cachexia Treatment Share (%), by Country
  • Figure 48. Asia Pacific Cachexia Treatment Share (%), by Country
  • Figure 49. Europe Cachexia Treatment Share (%), by Country
  • Figure 50. MEA Cachexia Treatment Share (%), by Country
  • Figure 51. North America Cachexia Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc (United States)
  • Merck & Co. Inc. (United States)
  • Aphios Corporation (United States)
  • Benuvia Therapeutics Inc (United States)
  • Alkem Labs (India)
  • Lannett (United States)
  • Ascent Pharmaceuticals, Inc (United States)
  • Akorn Incorporated (United States)
  • Endo International Inc (Ireland)
  • Hikma Pharmaceuticals PLC (United Kingdom)
  • Teva Pharmaceutical Industries Ltd (Israel)
Additional players considered in the study are as follows:
Wockhardt (India) , Breckenridge Pharmaceutical, Inc (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation